De-risking late-stage activities by retaining your early-stage expertise

Nolan Sutherland

28 August 2022

Editorial

Adherent versus suspension based platforms: what is the near future of viral vector manufacturing?

Ramin Baghirzade

09 November 2021

Editorial

Improving the yield of rAAV manufacturing with HeLa producer cells lines to ensure patient access

Matthew Fuller

05 October 2021

Editorial

CRISPR gene editing for sickle cell disease: one disease, differentiated approaches

Lisa A Michaels, MD, Bruce E Eaton, PhD

05 August 2021

Editorial

Expanding gene therapy and gene editing strategies to large and complex indications

Carmen Unzu, Florie Borel

30 June 2021

Editorial

Accelerating preclinical development for AAV based gene therapies: bridging the gap between discovery and clinical development

Louise Rodino-Klapac

24 February 2021

Editorial

Adherent systems for viral vector production

Hemant Dhamne, PhD

18 December 2020

Editorial

Process validation for recombinant adeno-associated virus vectors in rare diseases: challenges for MAAs

Catherine Cancian

16 May 2019

Editorial

Update on the Sleeping Beauty transposon system for therapeutic applications

Suneel A Narayanavari

06 December 2018

Editorial

Lentiviral vectors in hematopoietic stem cell therapies: mainstay technology, or simply a bridge to gene editing?

Marc Moore, John R Counsell

30 November 2018

Editorial

Emerging Automated Approaches for Cell and Gene Therapy Manufacture

Qasim Rafiq

20 November 2018

Editorial

Recent advances in non-viral vectors for gene therapy & vaccination

Clague Hodgson, Aaron E Carnes

29 March 2017

Editorial

Recent advances in the purification of recombinant adeno-associated virus

Rachid Benchaouir

04 October 2016

Editorial